Showing 551-560 of 9075 results for "".
Emerging Insights into the Immunologic Subtypes of Atopic Dermatitis
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/derm-hub/37142/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, a board-certified dermatologist in San Diego, California, and Director of Clinical Dermatology at Therapeutics Clinical Research, discusses how new understandings of the immunologic subtypes of atopic dermatitis should influence treatEncouraging Conversation
https://practicaldermatology.com/topics/skin-cancer-photoprotection/encouraging-conversation-40-gep-testing-for-adjuvant-radiation-therapy-candidates/37104/Two studies validate the 40-GEP test for identifying patients most likely to benefit from adjuvant radiation therapyAdvocacy and Research
https://practicaldermatology.com/series/the-practical-dermatology-podcast/advocacy-and-research/36479/The latest news and updates, plus Harrison Nguyen, MD, MBA, MPH, FAAD, discusses addressing barriers to maximizing biologics for psoriasis, and Mark Lebwohl, MD, FAAD, joins Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, to talk about some of the latest research he has been involvDr. Simpson Highlights Potentially Remittive Anti-OX40s at Maui Derm
https://reachmd.com/programs/practical-dermatology/dr-simpson-highlights-potentially-remittive-anti-ox40s-at-maui-derm/32920/Two anti-OX40 drugs in the pipeline may have remittive properties for atopic dermatitis, according to Eric Simpson, MD.SDPA: Dr. Matthew Zirwas Discusses Benefits of Attending the Annual Conference
https://practicaldermatology.com/conferences/sdpa-2024/sdpa-dr-matthew-zirwas-discusses-benefits-of-attending-the-annual-conference/29510/At the SDPA 22nd Annual Fall Dermatology Conference, Practical Dermatology caught up with Matthew Zirwas, MD. Dr. Zirwas shares why he looks forward to lecturing at the annual meeting.FDA Approves Bimzelx for Hidradenitis Suppurativa
https://practicaldermatology.com/series/dermwire-tv/fda-approves-bimzelx-hidradenitis-suppurativa/29518/In this week's DermwireTV, the FDA approves a new treatment for moderate to severe hidradenitis suppurativa; the FDA agrees to review the resubmission of Dupixent for the treatment of CSU; and the president of Merz Aesthetics, North America, joins us to discuss trends in the aesthetic market.SDPA: Medical Director Dr. Hilary Baldwin Discusses Acne and Keloids Lectures
https://practicaldermatology.com/conferences/sdpa-2024/sdpa-medical-director-dr-hilary-baldwin-discusses-acne-and-keloids-lectures/29508/At the SDPA 22nd Annual Fall Dermatology Conference, Practical Dermatology caught up with conference medical director Hilary Baldwin, MD. She explains the key takeaways of her lectures on acne and keloids.FDA Approves Rosacea Treatment Emrosi
https://practicaldermatology.com/series/dermwire-tv/fda-approves-rosacea-treatment-emrosi/29207/In this week's DermwireTV, the FDA approves a first-of-its-kind treatment for rosacea in adults; two companies with approved atopic dermatitis products provide new long-term efficacy and safety data; and Andrew Mastro discusses how to recognize physician burnout.Significant FDA Approval for PDT
https://practicaldermatology.com/series/pdt-in-practice/significant-fda-approval-pdt/29102/Dr. Jonathan S. Weiss discusses the importance of a recent FDA approval involving dosing of a PDT photosensitizer for both lesion-directed and field-directed treatment of actinic keratosis.Understanding Disparities in AD
https://practicaldermatology.com/series/updates-atopic-dermatitis/understanding-disparities-ad/29081/Dr. Raj Chovatiya, Clinical Associate Professor of Medicine at Rosalind Franklin University Chicago Medical School and Founder and Director of the Center for Medical Dermatology and Immunology Research, talks with Practical Dermatology about understanding disparities in atopic dermatitis and the soc